VYNE Therapeutics to Report First Quarter 2021 Financial Results on May 6, 2021

Rhea-AI Summary

VYNE Therapeutics Inc. (Nasdaq: VYNE) announced it will report its financial results for Q1 2021 on May 6, 2021, before market opens. A conference call will follow at 8:30 a.m. ET to discuss these results and provide a corporate update. VYNE focuses on developing innovative dermatological therapies, having received FDA approvals for AMZEEQ® and ZILXI®. Investors can access a replay of the call on VYNE's website post-event.

Positive

• FDA approval for AMZEEQ® and ZILXI® supports product pipeline.
• Upcoming conference call may provide insights into financial performance and future direction.

Negative

• None.

BRIDGEWATER, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the first quarter ended March 31, 2021, on Thursday, May 6, 2021, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.

Conference Call Details:

Thursday, May 6th @ 8:30am Eastern Time
Toll Free:	800-909-4985
International:	312-281-1211
Conference ID:	21993618
Webcast:	http://public.viavid.com/index.php?id=144542

A replay of the call will be archived on the Company’s website at www.vynetherapeutics.com after the conference call.

About VYNE Therapeutics Inc.
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.

With expertise in topical medicine innovation as a springboard, VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology (MST™), and has received FDA approval for AMZEEQ® (minocycline) topical foam, 4%, the world’s first topical minocycline, and for ZILXI® (minocycline) topical foam, 1.5%, the first minocycline product of any kind to be approved by the FDA for use in rosacea. For more information about our approved products, please see AMZEEQ’s Full Prescribing Information at AMZEEQ.com and ZILXI’s Full Prescribing Information at ZILXI.com.

For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com or follow VYNE on Twitter. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
646-889-1200
jallaire@lifesciadvisors.com

Andrew Saik
Chief Financial Officer
VYNE Therapeutics
908-731-6180
Andrew.Saik@vynetx.com

 

FAQ

When will VYNE report its Q1 2021 financial results?

VYNE will report its Q1 2021 financial results on May 6, 2021.

What time is the VYNE conference call scheduled?

The VYNE conference call is scheduled for 8:30 a.m. Eastern Time on May 6, 2021.

How can I access the VYNE conference call replay?

The replay of the VYNE conference call will be available on the company's website after the call.

What products has VYNE received FDA approval for?

VYNE has received FDA approval for its products AMZEEQ® and ZILXI®.

What is VYNE Therapeutics' main focus?

VYNE Therapeutics focuses on developing proprietary therapies in dermatology.